Key Takeaway: Enanta Pharmaceuticals has reported positive topline results from its Phase 2 study of Zelicapavir, aimed at treating Respiratory Syncytial Virus (RSV) in pediatric patients. Additionally, the company announced successful outcomes from a Phase 2a human challenge study of EDP-323 in healthy adults infected with RSV. These results highlight the potential of both therapies in addressing RSV infections.
Price reaction · baseline $11.235 (2024-10-02T14:14:00.000Z) · hit during market hours · clean, no other ENTA news in the window
day 0 close · peak
+0.1%
Market Sentiment Analysis
POSITIVE FACTORS
Positive topline results from a Phase 2 study in pediatrics.
Zelicapavir shows promise for treating Respiratory Syncytial Virus.
Successful Phase 2a study of EDP-323 in healthy adults.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~63 mo
Minimal dilution risk
Lead asset
EDP-235
Phase 2 · COVID-19
Full Press Release Details
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With RSV
Frequently Asked Questions
What are the results of the Zelicapavir study?
The study reported positive topline results for Zelicapavir in treating RSV in pediatric patients.
What is EDP-323 used for?
EDP-323 is being evaluated for its effectiveness in treating RSV in healthy adults.
What phase is the Zelicapavir study in?
The Zelicapavir study is currently in Phase 2.
Who conducted the RSV studies?
The studies were conducted by Enanta Pharmaceuticals.